# IMvigor 130 (NCT02807636)

> Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02807636
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Urothelial Carcinoma
- Interventions: Atezolizumab; Carboplatin; Gemcitabine; Placebo; Cisplatin
- Enrollment: 1213
- Primary outcome: Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
- Primary outcome: Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
- Primary outcome: Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 111
- Podcasts: 12
- YouTube: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imvigor-130-nct02807636

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02807636", "email": "<work email>"}; the inbox owner confirms by the emailed link.